Related Experiment Videos
Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization
Maryou B K Lambros1, Heike Fiegler, Angela Jones
1Molecular and Population Genetics Laboratory, Cancer Research UK, London, UK.
The Journal of Pathology
|December 9, 2004
Summary
This study identified frequent chromosomal changes in ovarian cancer cell lines, revealing two distinct types of ovarian cancer based on ploidy and genetic alterations. These findings highlight potential oncogenes and tumor suppressor genes for further investigation.
Area of Science:
- Genomics
- Cancer Biology
- Oncology
Background:
- Ovarian cancer is a heterogeneous disease with complex genetic underpinnings.
- Understanding chromosomal aberrations is crucial for classifying ovarian cancer subtypes and identifying therapeutic targets.
Purpose of the Study:
- To screen ovarian cancer cell lines for recurrent chromosomal changes using array-comparative genomic hybridization.
- To identify novel oncogenes and tumor suppressor genes associated with specific chromosomal alterations.
- To investigate the relationship between chromosomal instability and ovarian cancer subtypes.
Main Methods:
- Screening of 23 ovarian cancer cell lines using array-comparative genomic hybridization (aCGH).
- Analysis of large-insert clones at approximately 1 Mb density across the genome.
- Identification of recurrent chromosomal gains and losses, amplifications, and homozygous deletions.
Main Results:
- Frequent recurrent changes include loss of chromosome 4q, 18q, and gain of 20q.
- Two distinct ovarian cancer types identified: near-triploid with frequent changes and near-diploid/tetraploid with fewer changes.
- Novel amplifications (e.g., 11q13 including cyclin D1 and PAK1) and losses (e.g., CDKN2C, RASSF2) were detected, suggesting potential oncogenes and tumor suppressor loci.
Conclusions:
- Chromosomal instability patterns differ between ovarian cancer subtypes.
- Specific chromosomal regions harbor potential oncogenes (e.g., cyclin D1, PAK1, cyclin E) and tumor suppressor genes (e.g., CDKN2C, RASSF2).
- These findings provide a foundation for further research into ovarian cancer pathogenesis and targeted therapies.